1. To understand the treatment patterns of OACs and baseline patient characteristics of Japanese Non-Valvular Atrial Fibrillation (NVAF) patients 2. To determine whether warfarin and dabigatran new user group can be balanced using propensity score matching using pre-specified baseline covariates. 3. As an exploratory analysis, to assess mean duration of on-therapy follow-up time in database
Study Type
OBSERVATIONAL
Enrollment
48,696
NISED Center
Tokyo, Shinagawa, Japan
Number of Patients by Each Type of Study-target OAC Drug Prescribed for New Users of Anticoagulants With NVAF
Number of patients by each type of study-target OAC drug (dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban) prescribed as the first Oral Anticoagulants (OAC) with Non-valvular atrial fibrillation (NVAF)
Time frame: Day 1
Number of Patients Prescribed OAC Drug Dabigatran by Dosage
Number of patients prescribed OAC drug dabigatran at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
Time frame: Day 1
Number of Patients Prescribed OAC Drug Warfarin by Dosage
Number of patients prescribed OAC drug Warfarin at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
Time frame: Day 1
Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage
Number of patients prescribed OAC drug rivaroxaban at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
Time frame: Day 1
Number of Patients Prescribed OAC Drug Apixaban by Dosage
Number of patients prescribed OAC drug Apixaban at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
Time frame: Day 1
Number of Patients Prescribed OAC Drug Edoxaban by Dosage
Number of patients prescribed OAC drug edoxaban at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
Time frame: Day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Baseline Characteristics: Age
Baseline characteristics of patients in each treatment group: age
Time frame: 1 day
Baseline Characteristics: Gender
Baseline characteristics of patients in each treatment group: gender
Time frame: Day 1
Baseline Characteristics: Year of Initiating Treatment
Baseline characteristics of patients in each treatment group: year of initiating treatment
Time frame: Day 1
Baseline Characteristics: Speciality of Prescribers of OAC
Baseline characteristics of patients in each treatment group: speciality of prescribers of OAC. int.= internal; Med.= Medicine
Time frame: Day 1
Baseline Characteristics: History of Disease
Baseline characteristics of patients in each treatment group: history of disease and hospitalization.
Time frame: Day 1
Baseline Characteristics: History of Hospitalization
Baseline characteristics: history of hospitalization
Time frame: Day 1
Baseline Characteristics: AF Risk Score
Baseline characteristics of patients in each treatment group: Atrial Fibrillation (AF) risk score CHADS2: Congestive heart failure, Hypertension, Age, Diabetes, Stroke(doubled). CHADS2 score range from 0-6, with higher scores indicating the higher risk CHA2DS2VASc: Cardiac failure or dysfunction, Hypertension, Age 75 (doubled), Diabetes, Stroke (doubled) Vascular disease, Age 65-74 and Sex category (female) score. CHA2DS2VASc score range from 1-9, with higher scores indicating the higher risk. HAS-BLED: Hypertension, Abnormal renal function, Abnormal hepatic function. HAS-BLED score range from 0-8, with higher scores indicating the higher risk.
Time frame: Day 1
Baseline Characteristics: Concomitant Medication
Baseline characteristics of patients in each treatment group: concomitant medication
Time frame: Day 1